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Objectives: To evaluate the performance of the GeneXpert C. difﬁcile assay and C. diff Quik Chek Complete
(QCC) kit for the detection of toxins from fecal specimens and cooked meat broth (CMB) culture using
toxigenic stool culture as reference method, for the diagnosis of C. difﬁcile infection (CDI) in a community
setting.
Methods: Non-repeat stool samples were tested simultaneously by GeneXpert and QCC. Toxin detection
was done on neat stool samples, inoculated CMB, and isolated colonies.
Results: Nineteen (4.6%) of 409 samples were positive for glutamate dehydrogenase (GDH) in stool and
CMB by the QCC assay; seven (1.7%) were positive for both GDH and toxins A/B. The sensitivities of QCC
to detect C. difﬁcile toxin directly in stool specimens and CMB were 68.4% and 100%, respectively, while
speciﬁcities were 100% and 83%, respectively. C. difﬁcile toxin was detected in 10 (2.5%) specimens and 13
(3.2%) CMB. Thirteen (68.4%) of 19 isolates were positive for C. difﬁcile toxin by GeneXpert and QCC and
were taken as the reference toxigenic culture. The disease burden was thus 3.2%. The sensitivities of
GeneXpert in stool and CMB were 81.3% and 100%, respectively, while speciﬁcities were 100% and 100%,
respectively.
Conclusion: The GeneXpert assay was more sensitive than QCC for the detection of C. difﬁcile toxin in
stool, but both assays were highly speciﬁc.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Clostridium difﬁcile, a strictly anaerobic Gram-positive spore-
forming rod, is part of the normal gut ﬂora of humans. It is the
leading cause of healthcare-associated diarrhea in Western and
industrialized countries.1–3 During C. difﬁcile infection (CDI), C.
difﬁcile usually produces two extracellular toxins that lead to tissue
damage of the colon and clinical symptoms. The incidence and
severity of CDI are on the ascendancy.4 However, in many
developing countries, CDI remains under-recognized, under-
diagnosed, and thus under-reported. Therefore, the cycle of
transmission is continued.
CDI is associated with a signiﬁcant clinical burden on
healthcare facilities due to its severity, e.g., life-threatening
pseudomembranous colitis (PMC), toxic megacolon, perforation* Corresponding author. Tel.: +965 2498 6781; fax: +965 2533 2719.
E-mail address: wjamal@hsc.edu.kw (W. Jamal).
http://dx.doi.org/10.1016/j.ijid.2014.10.025
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).of the colon, sepsis, and death.1,5,6 Infection control measures to
prevent horizontal or healthcare-associated transmission further
increase the cost of CDI in the healthcare setting. Unlike other
enteric infections, CDI is often associated with an elevated rate of
recurrent episodes (either relapse or re-infection) and treatment
failure. The diagnosis of CDI is dependent on the presence of both
diarrhea (deﬁned as the passing of three or more unformed stools
within a 24-h period) and a positive laboratory test for the
presence of toxigenic C. difﬁcile in the stool.7 The rapid and accurate
diagnosis of CDI is important for appropriate management of the
patient as well as for the implementation of infection control
measures and efﬁcient surveillance.
Several laboratory tests are available for the detection of
C. difﬁcile or its toxin in the feces, including the following: cell
culture cytotoxicity neutralization assays (CCNA), toxigenic
culture, toxin/antigen detection, and detection of toxin genes
by nucleic acid ampliﬁcation tests. Traditionally, the diagnosis of
CDI has depended on cytotoxigenic culture, which is done by
culturing the stool for C. difﬁcile and then performing a cytotoxinciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
W. Jamal et al. / International Journal of Infectious Diseases 29 (2014) 244–248 245assay on the isolate.8 Cytotoxigenic culture is labor-intensive,
subjective, time-consuming, has a long turnaround time (around
3 days), and requires speciﬁc laboratory facilities and technical
expertise, all of which limit its use in clinical practice. Therefore,
many clinical laboratories adopt other tests, e.g., enzyme
immunoassays (EIAs) that target toxins A and/or B or glutamate
dehydrogenase (GDH), which are relatively cheaper, faster, and
easier than the CCNA assay. However, a major drawback of the EIA
toxins A/B assays is their lack of sensitivity (33–65%), thus they
are not recommended as a standalone detection method.2,7,9,10 In
contrast, GDH assays have high sensitivity but poor speciﬁcity,
therefore a positive GDH sample must be subjected to another EIA
test to detect toxins A/B, making the use of EIA-based detection
assays a rather complicated and time-consuming approach.2,9,10
Another relatively new development is the application of real-
time PCR targeting the tcdB gene of C. difﬁcile directly from the
stool. It has high sensitivity and speciﬁcity compared to EIA.11
However, the main disadvantage of PCR is that it does not detect
the biologically active toxin in the stool and it fails to discriminate
between CDI and asymptomatic colonization with C. difﬁcile;
therefore it requires interpretation along with the patient’s
clinical data.
This study was designed to compare the performance of the
GeneXpert C. difﬁcile assay (Cepheid, CA, USA) and C. diff Quik
Chek Complete kit (QCC) (TechLab, VA, USA) for the detection of C.
difﬁcile antigen and toxins directly from fecal specimens, cooked
meat broth (CMB) culture, and C. difﬁcile colonies, for the diagnosis
of CDI in a community setting.
2. Materials and methods
2.1. Stool samples
A total of 416 non-repeat stool specimens were collected from
patients with diarrhea who were aged over 2 years. This was a
prospective study conducted at the Anaerobe Reference Laborato-
ry, Mubarak Al Kabir Hospital, Kuwait over a period of 6 months
(July to December 2012). The patients, who had community-onset
symptoms, were seen at the outpatient clinics of Adan, Amiri,
Farwaniya, Jahra, Mubarak Al Kabir, and Sabah hospitals. The
specimens tested were unformed stools, collected in sterile wide-
mouthed screw-capped stool containers, deﬁned as specimens
that took the form of the collection container at room temperature.
Specimens were stored, when necessary, in a refrigerator and
tested by EIA and GeneXpert. They were also cultured within 48 h
after collection for C. difﬁcile and other enteric pathogens on
appropriate selective and non-selective media.
2.2. GeneXpert C. difﬁcile PCR assay
The Xpert C. difﬁcile assay, a real-time PCR, was carried out in
accordance with the manufacturer’s instructions. The ﬁrst step was
to dip a swab into the unformed stool sample. This was then placed
in sample reagent, capped, and vigorously mixed by vortex for 10 s.
All the liquid from the sample reagent was transferred by large
transfer pipette (Cepheid) into the ‘S’ chamber of the cartridge.
Reagent 1 was added to chamber 1 of the test cartridge. The last
step involved the addition of reagent 2 to chamber 2 of the test
cartridge, followed by closure of the lid. The cartridge barcode was
then scanned and the cartridge placed in the GeneXpert instru-
ment. The resulting data were interpreted as positive, negative, or
invalid. The same procedure was carried out on the inoculated
Robertson CMB (Oxoid Ltd, Basingstoke, Hampshire, UK) and the
cultured colony emulsiﬁed in sample/elution reagent (guanidi-
nium thiocyanate and surfactants; Cepheid).2.3. Enzyme immunoassays (EIA)
GDH antigen and/or toxins were detected by QCC, which was
performed in accordance with the manufacturer’s instructions.
Brieﬂy, 25 ml or an equivalent volume of stool sample was added to
a tube containing the diluent and conjugate (TechLab), and the
mixture was transferred to the device sample well. After
incubation for 15 min at room temperature, the wash buffer
(TechLab) and then the substrate (TechLab) were added to the
reaction window. The results were read 10 min later. GDH antigen
and/or toxins were reported positive if a visible band was seen on
the antigen and/or toxin side of the device display window,
respectively. The same procedure was carried out for the
inoculated CMB and the isolated colony emulsiﬁed in sterile
sample/elution reagent (Cepheid).
2.4. Toxigenic culture (TC)
An aliquot of unformed stool sample was inoculated into CMB,
selected with sodium taurocholate (0.05%; Alfa Aesar Ltd,
Heysham, UK), lysozyme (5 mg/l; Sigma-Aldrich, Poole, UK),
cycloserine (500 mg/l; Bioconnections, Wetherby, UK), and cefox-
itin (16 mg/l, Bioconnections), after autoclaving.12 It was incubated
at 37 8C in an anaerobic environment of Anoxomat (Mart
Microbiology B.V., Drachten, the Netherlands) for 48 h. Then,
500 ml of the CMB culture was heated for 10 min at 80 8C. After
cooling, one loop of the heated broth was inoculated onto a pre-
reduced cycloserine–cefoxitin–fructose agar (CCFA; Oxoid Ltd)
supplemented with 5% sheep blood and incubated at 37 8C for up to
5 days before a ﬁnal interpretation of the result. The CCFA agar was
examined for representative colonies at 2 and 5 days. Presumed
colonies characteristic of C. difﬁcile (yellow ﬂat colonies) were
examined for p-cresol odor (unique to C. difﬁcile), characteristic
morphology, Gram stain (i.e., large Gram-positive rods), obligate
anaerobic growth requirement, and identiﬁcation by API AN
(bioMe´rieux, Marcy l’Etoile, France). For positive cultures, a single
isolated C. difﬁcile colony was tested for toxin production with both
the QCC kit and GeneXpert C. diff PCR assay, as described above.
2.5. Analysis
A combination standard was deﬁned as concordant results for
two or more of the following assays: sensitivity, speciﬁcity, and
positive and negative predictive values (PPV and NPV, respective-
ly) were determined.
3. Results
3.1. Results of the GeneXpert C. diff assay and QCC compared to TC
Of the 416 stool specimens, seven were excluded because of
insufﬁcient volume. Consequently, 409 (98.3%) specimens were
included in the study. The results of each assay were compared to
the results of TC and discrepant specimens were resolved by TC.
The detection of C. difﬁcile toxin was carried out on stool samples,
samples inoculated and incubated in CMB, and cultured colonies. A
total of 19 isolates were detected, giving a prevalence of 4.7%
carriage/infection in the community. Thirteen (68.4%) of these
isolates produced toxin with simultaneous detection of toxin in the
stool samples.
The comparison of test results for the GeneXpert C. diff assay
and QCC assay against the TC assay is shown in Table 1. Of the
409 stool specimens and simultaneous 409 CMB tested, QCC
detected GDH in 19 samples; however, it detected toxin in only
seven (36.8%) stool samples and 14 (73.7%) inoculated CMB. All
19 GDH-positive samples also yielded C. difﬁcile by culture.
Table 1
Comparison of GeneXpert C. difﬁcile assay and C. diff Quik Chek Complete assay
with toxigenic culture
Specimen Toxin detection directly
from stool
Toxin detection in CMB TC
GeneXpert QCC GeneXpert QCC
1 Negative Negative Negative Negative Negative
2 Positive Positive Positive Positive Positive
3 Negative Positive Positive Positive Positive
4 Positive Positive Positive Positive Positive
5 Negative Positive Positive Positive Positive
6 Negative Negative Negative Negative Negative
7 Positive Positive Positive Positive Positive
8 Positive Positive Positive Positive Positive
9 Negative Negative Negative Negative Negative
10 Positive Positive Positive Positive Positive
11 Negative Negative Negative Negative Negative
12 Negative Negative Positive Positive Positive
13 Positive Negative Positive Positive Positive
14 Positive Negative Positive Positive Positive
15 Negative Negative Negative Positive Negative
16 Positive Negative Positive Positive Positive
17 Negative Negative Negative Negative Negative
18 Positive Negative Positive Positive Positive
19 Positive Negative Positive Positive Positive
CMB, cooked meat broth; QCC, C. diff Quik Chek Complete assay; TC, toxigenic
culture.
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19 stool samples and 13 (68.4%) CMB. TC was positive in 13 (68.4%)
stool and CMB samples, with simultaneous positivity for C. difﬁcile
toxin genes (tcdB) and toxin A and B with GeneXpert and QCC,
respectively.
Table 2 shows the analysis of shared results of the specimens by
the two assay methods grouped into six arbitrary clusters. Group
1 contains six samples each of stool and CMB that were
consistently negative in all tests and the TC gold standard. Group
2 contains ﬁve stool and ﬁve CMB samples that were positive in all
tests, as well as by TC. The next notable cluster is group 4, in which
four samples were positive by GeneXpert and TC, but negative by
QCC direct testing on stool; all four were positive in CMB. There
were two samples in group 3 that were negative by GeneXpert in
direct stool testing but positive by QCC and TC in both stool and
CMB. One sample in group 6 was negative by GeneXpert, QCC, and
TC in direct stool testing, and positive only by QCC in CMB.
3.2. Sensitivity, speciﬁcity, PPV, and NPV
The sensitivity, speciﬁcity, PPV, and NPV are presented in
Table 3. Overall, with the QCC, seven (1.7%) stool specimens were
positive for both GDH and toxins A/B (true-positives) and 12 (2.9%)Table 2
Analysis of shared test results of specimens/assays
Specimen
group
(number)a
Test results TC
Direct toxin
detection in stool
Toxin detection
in CMB
GeneXpert QCC GeneXpert QCC
1 (n = 6) Negative Negative Negative Negative Negative
2 (n = 5) Positive Positive Positive Positive Positive
3 (n = 2) Negative Positive Positive Positive Positive
4 (n = 4) Positive Negative Positive Positive Positive
5 (n = 1) Negative Negative Positive Positive Positive
6 (n = 1) Negative Negative Negative Positive Negative
CMB, cooked meat broth; QCC, C. diff Quik Chek Complete assay; TC, toxigenic
culture.
a Arbitrary specimen grouping based on shared results.were positive for GDH and negative for toxin A/B (false-positive). A
total of 390 (95.4%) stool samples and CMB were negative for both
GDH and toxins A/B (true-negative). The sensitivities of the QCC
assay for direct toxin detection in stool and in CMB were 68.4% and
100%, respectively, and speciﬁcities 100% and 83%, respectively.
The PPV and NPV of the test in stool and CMB were 100% and 92.9%,
and 50% and 100%, respectively. In comparison, the sensitivity and
speciﬁcity of the GeneXpert assay for direct toxin detection in stool
were 81.3% and 100%, respectively, while the sensitivity and
speciﬁcity for the detection of toxin in CMB were 100% and 100%,
respectively. The PPV and NPV of stool and CMB testing were 100%
and 66.7%, and 100% and 100%, respectively. The disease
prevalence among the 19 GDH-positive samples was 68.4%.
4. Discussion
The laboratory diagnosis of CDI continues to be an important
issue due to the increase in incidence and severity of CDI.1,6,13
However, the diagnosis of CDI remains a challenge for many
clinical microbiology laboratories. Different tests have emerged to
diagnose CDI, but no single test approach has been proven effective
to satisfy the need of all patients, hospitals, and clinical
microbiology laboratories. The selection of C. difﬁcile testing and
the testing procedures are dependent on each laboratory,
institution, and patient population. There is a lot of debate
regarding the gold standard method for C. difﬁcile testing. The US
Food and Drug Administration (FDA) has continuously chosen the
cytotoxic neutralization assay over TC as its standard for the
diagnosis of CDI.14 The latest guidelines from the Society for
Healthcare Epidemiology of America and the Infectious Diseases
Society of America have re-emphasized the two-step algorithms
that utilize GDH assay screening for C. difﬁcile in stool samples
followed by the cell culture neutralization assay, toxigenic culture,
or nucleic acid ampliﬁcation test to identify toxin-producing C.
difﬁcile strains.7
GDH is a stable protein produced by C. difﬁcile and other
Clostridium species and is used as a marker for the presence of the
organism. The sensitivity of GDH assays varies between 70% and
100% compared to toxigenic culture and/or PCR.2,15,16 In our hands,
the detection of toxin A/B by QCC assay had a sensitivity of 68.4%
and speciﬁcity of 100%. However, Alcala et al. reported a lower
sensitivity and speciﬁcity of 54.9% and 95.5%, respectively, for the
detection of toxin A/B with this method.15 In contrast, Eastwood
et al. and Miendje Deyi et al. reported higher sensitivities of 84.3%
and 96%, respectively, for the detection of toxin A/B, and almost
similar speciﬁcities to ours, 98.9% and 100%, respectively.16,17
A major ﬁnding of this work is that the GeneXpert assay is
substantially better than the QCC assay performed. The sensitivi-
ties of QCC from stool and CMB testing were similar in value to
those reported in previous studies in which the performance of the
QCC was compared to either toxigenic culture or the
CCNA.9,10,16,18,19 The detection level of C. difﬁcile toxin by QCC
was relatively lower than by GeneXpert when detecting toxin
directly in stool samples. Also, when compared with TC, the
detection levels of both QCC and GeneXpert were relatively lower
in stool samples compared to the detection levels in CMB using TC
as the gold standard.
Combined tests, using both TC and toxin detection in CMB, gave
a CDI prevalence of 3.2% in the community, which may be
explained by the low incidence of CDI in Kuwait in general.20
However, other studies have related the low detection capacity of
the EIA directly from stool specimens to the degradation of the
toxin in the stool specimens.21 Furthermore, inter-strain variabili-
ty in toxin expression, the C. difﬁcile concentration, or a toxin
dilution below the limit of detection in some patients due to an
Table 3
Sensitivity and speciﬁcity of the GeneXpert C. difﬁcile PCR assay and C. diff Quik Chek Complete assay for the detection of Clostridium difﬁcile toxina
Specimen
(number of
samples tested)
Toxin detection assay Specimens
showing C. difﬁcile
toxin positive (n = 13)
Test performance
Sensitivity (%) Speciﬁcity (%) PPV NPV
Direct toxin in stool
(N = 409)
GeneXpert C. difﬁcile PCR assay 10 76.92 100 100 99.25
C. diff Quik Chek Complete assay 7 53.85 100 100 98.51
Toxin detection in CMB
(N = 409)
GeneXpert C. difﬁcile PCR assay 13 100 100 100 100
C. diff Quik Chek Complete assay 14 100 99.75 92.86 100
PPV, positive predictive value; NPV, negative predictive value; CMB, cooked meat broth.
a For the GeneXpert tests: sensitivity, 95% conﬁdence limits (Cl) 46.20–94.69%; speciﬁcity, 95% Cl 99.06–100.00%; PPV, 95% Cl 68.97–100.00%; NPV, 95% Cl 97.82–99.84%;
disease prevalence = 3.18%, 95% Cl 1.70–5.37%; negative likely ratio = 0.23, 95% Cl 0.09–0.62. C. diff Quik Chek: sensitivity, 95% Cl 25.22–80.67%; speciﬁcity, 95% Cl 99.06–
100.00%; PPV, 95% Cl 58.93–100.00%; NPV, 95% Cl 96.78–99.45%; disease prevalence = 3.18%, 95% Cl 1.70–5.37%; negative likely ratio = 0.46, 95% Cl 0.26–0.83.
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for a low detection capacity of the EIA.16,21,22
In the present study, it is interesting to note that for two of the
patients with CDI, both the QCC and GeneXpert did not detect the
toxin directly from the stool specimen; instead it was detected
from CMB and conﬁrmed by TC. This may suggest that there was a
low concentration of the toxin in the samples, below the detection
limit of the test, and that the use of selective broth ampliﬁcation in
CMB and of the culture technique dramatically increased the yield.
A similar study, reporting ﬁndings consistent with ours, has
reported the use of selective broth pre-ampliﬁcation and real-time
PCR detection for asymptomatic C. difﬁcile carriage, but not CDI,
from peri-rectal swabs.23 A false-positive toxin production result
by the QCC was also noted in one CMB sample, which was resolved
by TC. This sample was negative by both test systems in direct stool
testing and negative by GeneXpert and TC in CMB. It is conceivable
that the GDH detected was as a result of the presence of Clostridium
spp other than C. difﬁcile.
Both the sensitivity and speciﬁcity of GeneXpert for the
detection of C. difﬁcile toxin in stool specimens and CMB in our
study were higher than other reported sensitivities and speciﬁcities
for this assay, which have varied between 91.7% and 95.2%, and
between 94% and 95.2%, respectively.24,25 However, it has been
recommended that due to the enhanced sensitivity of the assay that
detects the tcdB gene and not the toxin itself, the use of this assay
should be limited to patients with clear clinical symptoms of CDI.26
One limitation of our study is that the preferred gold standard,
the cell culture cytotoxicity assay (CCA), was not used. However, an
accepted toxigenic culture was used as the reference test system.
This approach could potentially have affected the overall
sensitivity and speciﬁcity of the assay, with a particular risk of
overestimating the sensitivity of the molecular method. The CCA
appears to be superior to TC, as demonstrated by a very interesting
and recently published prospective multicenter study that
evaluated the two standard reference methods according to the
clinical outcome and the optimum laboratory diagnosis of CDI.27 In
that study, it was found that the CCA correlated best with the cases
of CDI and the clinical outcome, and also deﬁned the true cases of
CDI.27 A new diagnostic category of potential C. difﬁcile excretor,
deﬁned as TC-positive but CCA-negative, could be used to
characterize patients with diarrhea that is probably not due to
C. difﬁcile infection but who can cause cross-infection.27
Another important limitation of our study is the low prevalence
of CDI in community patients demonstrated in this study. Although
previous prospective studies in Kuwait have indicated that CDI is
the most common cause of hospital-acquired diarrhea, its overall
prevalence has been consistently and relatively low at 9%20 and
8.03%28 among hospitalized patients. As suspected, given this
background, it was not too surprising that the prevalence of C.
difﬁcile infection/colonization in the community was 4.7% and the
disease burden 3.2%. The low prevalence of the disease in Kuwait
may be attributable to a lack of awareness on the part of cliniciansconcerning the clinical diagnosis of the disease. The results of this
study now provide documented evidence that the disease is not a
big problem in Kuwait compared to the high prevalence rates in
Western countries.
In conclusion, GeneXpert was user-friendly, fully automated,
and had a short turnaround time, compared to the QCC. Although it
is more expensive than the QCC, it is more sensitive in direct toxin
detection in stool and more speciﬁc in CMB. It provides a more
rapid diagnosis and prompt clinical recognition of patients with
CDI, which is imperative not only for patient management but also
for infection prevention and control; only patients with active
disease could be isolated, saving the hospital the costs of the
isolation policy as well as the patient from being isolated
unnecessarily. Testing stool directly and in CMB enhanced the
detection levels of both test systems. We therefore recommend an
algorithm of testing for the antigen (GDH) by QCC and then
subjecting the positive samples to toxin detection directly in stool
and CMB by GeneXpert.
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